MedWatch

IO Biotech expands collaboration with MSD – begins phase II trial

IO Biotech is initiating a third clinical collaboration with partner MSD to develop a combination treatment for three types of cancer, comprised of MSD's blockbuster drug Keytruda and IO Biotech's lead candidate. A phase II trial is on its way, and should it prove successful, IO Biotech will maintain global commercial rights.

Mai-Britt Zocca, CEO and founder of IO Biotech, has signed off on the Danish cancer company's third deal with US-based MSD | Photo: IO Biotech / PR

Danish cancer company IO Biotech is entering its third clinical collaboration with US-based pharmaceutical giant MSD. The ambition is to develop a drug for the treatment of three different types of cancer, it reports in a press release.

IO Biotech, which recently went public on the stock exchange in the US, wants to test its immune-modulating cancer therapy, IO102-IO103, in combination with MSD's multi-blockbuster drug Keytruda (pembrolizumab).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs